Category: Johnson & Johnson
Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter
Healthcare giant Johnson & Johnson plans to repurchase up to $5 billion of its own shares over an indefinite amount of time.
Johnson & Johnson (NYSE:JNJ) last night announced that its board of directors approved a $5 billion open-ended repurchase program for shares of the company's common stock.
Johnson & Johnson CEO Alex Gorsky says the healthcare giant is eyeing acquisitions to bolster its 'subscale' cardiovascular business and, possibly, other aspects of its medical device business.
The world's largest medical device operation is eyeing acquisitions to bolster its "subscale" cardiovascular business, particularly its electrophysiology business, Johnson & Johnson (NYSE:JNJ) chairman & CEO Alex Gorsky told analysts yesterday.
Johnson & Johnson's pharmaceuticals division helps buoy the healthcare giant to another beat & raise quarter, but its medical device division again fails to meet expectations.
Here's a look at some of the top legal news stories for medical device companies this week: Guidant can't slip breach-of-contract charges in Johnson & Johnson suit; Biomet reveals SEC subpoena over alleged 'improprieties' in Brazil, Mexico; Appeals court upholds Retractable Technologies win over Becton Dickinson; Board suspends ex-PricewaterhouseCoopers accountant over ArthroCare scandal; Covidien's Nellcor and CAS Medical settle dispute for $275k
, Becton Dickinson & Co.
, Boston Scientific
, CAS Medical Systems Inc.
, Dept. of Justice (DOJ)
, Guidant Corp.
, Johnson & Johnson
, Public Company Accounting Oversight Board
, Retractable Technologies Inc.
, Securities & Exchange Commission (SEC)
, Abbott Laboratories
An FDA panel convened last week to evaluate the use of laparoscopic power morcellators in removing uterine fibroids, implicated in spreading cancer, failed to reach a consensus on their safety despite outraged testimony from physicians and attendees at the hearing.
An FDA panel convened last week to consider the use of a controversial procedure to remove uterine fibroids failed to come to a clear decision on the cancer risk from laparoscopic power morcellators, despite outraged testimony from dozens of attendees.
Here's a look at some of the top regulatory stories for medical device companies this week: Covidien taps integration chief to navigate Medtronic merger; Zimmer, Biomet appoint integration team; Thoratec inks $75M deal for Apica Cardiovascular; FTC wants more from Zimmer, Biomet on merger; Johnson & Johnson closes Ortho-Clinical Diagnostics sale